Puig slowdown clouds Estée Lauder deal hopes, turnaround gets tougher

What happened

Estée Lauder's planned acquisition of Puig faces a new hurdle after Puig reported its slowest quarterly growth since the pandemic, dampening hopes for a quick sales boost from the deal. The weak Puig results underscore the broader headwinds in prestige beauty, especially in Asia travel retail and China, which have already driven EL's FY2025 to a $1.1B net loss. While EL's PRGP restructuring has shown early margin improvement in Q1 FY2026, the company remains highly leveraged with net debt/EBITDA at 34x and negative interest coverage. The stock has rallied ~29% over the past year, pricing in a rapid turnaround that is not yet validated by sustainable free cash flow normalization. This latest development pushes the expected recovery further out, reinforcing the need for disciplined patience rather than aggressive entry.

Implication

Investors should wait for 2-3 consecutive quarters of organic sales growth and clear deleveraging before re-evaluating. The Puig deal's struggles remove a key catalyst but avoid integration risk; focus on EL's own operational execution.

Thesis delta

The Puig news weakens the bullish thesis that EL could accelerate recovery through acquisitions, suggesting organic turnaround may be slower. The stock's premium valuation is even harder to justify, and the probability of an upgrade to BUY in the next 6 months has decreased. My stance remains WAIT with a lower likelihood of near-term improvement.